A New Era in Heart Failure Treatment with the MAGLEV-Based BiVACOR Artificial Heart

Muhammed Kemal Kahyalar

For patients with end-stage heart failure, artificial hearts have long been used as bridge-to-transplant therapies. However, conventional systems are typically valve-based, air-driven, and dependent on external drivers. In 2024, the BiVACOR artificial heart implanted in Australia drew global attention as the first valveless total artificial heart equipped with magnetic levitation (MAGLEV) technology. This article compares traditional Total Artificial Heart (TAH) applications at the Cleveland Clinic with the BiVACOR system, discussing future implications and clinical potential.

The BiVACOR Artificial Heart and Clinical Application

The BiVACOR device operates on a rotor system with only a single moving part. The rotor is suspended within the housing via magnetic levitation, allowing frictionless rotation. This structure mimics both left and right ventricular function. Blood flow direction is regulated by impellers located at each end of the rotor. In the 2024 Australian clinical case, the patient lived for 100 days with this artificial heart without the need for an external driver, marking a major milestone in mechanical circulatory support.

Cleveland Clinic and the Total Artificial Heart (TAH)

In the traditional TAH systems used at the Cleveland Clinic, the native ventricles are removed and replaced with mechanical pumps. These systems depend on external pneumatic drivers and generally provide temporary support until a donor heart becomes available. In successful cases, 60–80% of patients can progress to transplantation.

Advantages of MAGLEV (Magnetic Levitation) Technology

MAGLEV technology enables frictionless motion of the device’s moving components, significantly reducing mechanical wear and thrombus formation. By incorporating this technology, BiVACOR is designed for long-term durability. Additionally, the adjustable rotor speed allows for pulsatile, physiologic-like blood flow, an important advantage over continuous-flow devices.

Comparative Assessment

Mechanical Design:
TAH systems contain valves and multiple mechanical components, whereas BiVACOR uses a single-rotor architecture.
Portability:
TAH devices require a large external console; BiVACOR is more compact and capable of operating independently.
Circulatory Mechanism:
TAH systems rely on pneumatic pressure, while BiVACOR functions through rotor-driven modulation of flow.
Complication Risk:
Reduced friction in the BiVACOR system minimizes mechanical complications and lowers thrombotic risk.

The BiVACOR artificial heart represents a promising alternative for patients with advanced heart failure, either as a bridge until a donor heart becomes available or potentially as a long-term permanent therapy. The advantages introduced by MAGLEV technology offer opportunities for developing durable solutions that go beyond the limitations of traditional artificial heart systems.